Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P16471

UPID:
PRLR_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P16471; B2R882; D1MDP1; Q16354; Q8TD75; Q8TD78; Q96P35; Q96P36; Q9BX87; Q9UHJ5

BACKGROUND:
Encoded by the gene P16471, the Prolactin Receptor is essential for mediating the effects of prolactin, a hormone integral to reproductive health and lactation. It functions as a prosurvival factor for spermatozoa, showcasing the receptor's significance beyond traditional lactation roles. The receptor's complexity is further illustrated by the inability of certain isoforms to signal prolactin, indicating a nuanced regulatory mechanism.

THERAPEUTIC SIGNIFICANCE:
Given the Prolactin Receptor's critical role in conditions like Hyperprolactinemia and Multiple fibroadenomas of the breast, its study offers a promising avenue for the development of targeted therapies. The receptor's influence on disease mechanisms provides a foundation for exploring novel therapeutic strategies, potentially transforming treatment paradigms for prolactin-mediated disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.